Skip to main content

Pluvicto Disease Interactions

There are 2 disease interactions with Pluvicto (lutetium lu 177 vipivotide tetraxetan).

Moderate

Lutetium Lu 177 vipivotide tetraxetan (applies to Pluvicto) myelosuppression

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts, Immunodeficiency

Lutetium Lu 177 vipivotide tetraxetan can cause severe and life-threatening myelosuppression (including anemia, thrombocytopenia, leukopenia, neutropenia); caution is recommended in at-risk patients. Complete blood counts should be performed before and during therapy.

Switch to professional interaction data

Moderate

Lutetium Lu 177 vipivotide tetraxetan (applies to Pluvicto) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Exposure of lutetium Lu 177 vipivotide tetraxetan is expected to increase with the degree of renal dysfunction. No dose adjustment is recommended for patients with mild (baseline CrCl 60 to 89 mL/min by Cockcroft-Gault) to moderate (CrCl 30 to 59 mL/min) renal dysfunction; as these patients may be at greater risk of toxicity, renal function and adverse reactions should be monitored frequently. Pharmacokinetics and safety of lutetium Lu 177 vipivotide tetraxetan have not been studied in patients with severe (CrCl 15 to 29 mL/min) renal dysfunction or end-stage renal disease; caution is advised in these patients.

Switch to professional interaction data

Pluvicto drug interactions

There are 211 drug interactions with Pluvicto (lutetium lu 177 vipivotide tetraxetan).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer